Matches in Wikidata for { <http://www.wikidata.org/entity/Q37473017> ?p ?o ?g. }
- Q37473017 description "article científic" @default.
- Q37473017 description "article scientifique" @default.
- Q37473017 description "articolo scientifico" @default.
- Q37473017 description "artigo científico" @default.
- Q37473017 description "artículu científicu espublizáu en 2013" @default.
- Q37473017 description "bilimsel makale" @default.
- Q37473017 description "scientific article published on 21 October 2013" @default.
- Q37473017 description "vedecký článok" @default.
- Q37473017 description "vetenskaplig artikel" @default.
- Q37473017 description "videnskabelig artikel" @default.
- Q37473017 description "vědecký článek" @default.
- Q37473017 description "wetenschappelijk artikel" @default.
- Q37473017 description "wissenschaftlicher Artikel" @default.
- Q37473017 description "наукова стаття, опублікована в жовтні 2013" @default.
- Q37473017 description "научни чланак" @default.
- Q37473017 description "مقالة علمية نشرت في 21 أكتوبر 2013" @default.
- Q37473017 name "Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years" @default.
- Q37473017 name "Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years" @default.
- Q37473017 name "Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years" @default.
- Q37473017 type Item @default.
- Q37473017 label "Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years" @default.
- Q37473017 label "Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years" @default.
- Q37473017 label "Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years" @default.
- Q37473017 prefLabel "Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years" @default.
- Q37473017 prefLabel "Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years" @default.
- Q37473017 prefLabel "Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years" @default.
- Q37473017 P1433 Q37473017-21541236-0DC2-4210-BE0B-77EE571CAD22 @default.
- Q37473017 P1476 Q37473017-AC95B1A8-FEE8-4E16-B990-D1356AE04E4F @default.
- Q37473017 P2093 Q37473017-2B83E321-C858-48DB-AA82-117E1618F064 @default.
- Q37473017 P2093 Q37473017-32484C2D-31B0-46E8-8E35-97BACF8EDF96 @default.
- Q37473017 P2093 Q37473017-325E3BFA-A526-43CF-9536-486047230A3A @default.
- Q37473017 P2093 Q37473017-328B4926-3ECC-4787-8A33-7546A81D9D59 @default.
- Q37473017 P2093 Q37473017-5100D441-62F7-47A5-A4B2-C4A91CD5810A @default.
- Q37473017 P2093 Q37473017-78B257D9-F0B4-474F-840B-3CAC77BFB66E @default.
- Q37473017 P2093 Q37473017-7AB28DAF-9513-4A40-8EC1-1B9592596452 @default.
- Q37473017 P2093 Q37473017-8002CF0F-89A2-4DFB-92AE-335BE33A9FF6 @default.
- Q37473017 P2093 Q37473017-95943244-9F94-4165-8241-07220277D27B @default.
- Q37473017 P2093 Q37473017-B1779498-BCAB-43C2-8812-01968301FA90 @default.
- Q37473017 P2093 Q37473017-CEB460F2-D2FC-4D70-B971-378062E056B5 @default.
- Q37473017 P2093 Q37473017-D29AF801-2D30-47AC-9446-92585A9AF8D8 @default.
- Q37473017 P2093 Q37473017-E258CEC4-A6AC-45C4-9ABA-F78851B9970F @default.
- Q37473017 P2860 Q37473017-1C71A37A-7769-4978-B07A-5E06D69E451F @default.
- Q37473017 P2860 Q37473017-359BC2D7-C7BA-4159-8F9E-DAD561CA4E1A @default.
- Q37473017 P2860 Q37473017-4527A005-C988-4F5E-8B21-533FFEBF615B @default.
- Q37473017 P2860 Q37473017-49EEDDC1-ED2C-409F-95C1-7F6E7E4F5634 @default.
- Q37473017 P2860 Q37473017-7DC1F63B-20DA-4F21-92C2-1511DB0DF2A8 @default.
- Q37473017 P2860 Q37473017-8D32125E-37FA-488A-A455-734E83E7D002 @default.
- Q37473017 P2860 Q37473017-A989BD3A-D736-40DB-8FB9-D2E5ADD8544A @default.
- Q37473017 P2860 Q37473017-B7301303-4BAC-4D09-A045-123EE8F48F7E @default.
- Q37473017 P2860 Q37473017-CFE02E6B-5469-4E5E-8158-EB65941556E0 @default.
- Q37473017 P304 Q37473017-6BAE646C-8C69-4C81-A329-045EA22E802C @default.
- Q37473017 P31 Q37473017-C095618B-AC87-4463-B0D3-AE11EFFCF146 @default.
- Q37473017 P356 Q37473017-3AE96397-8F4F-4F5D-87FC-643C7D1FAD67 @default.
- Q37473017 P407 Q37473017-1D0D6FF0-FCB7-4C68-92F3-696AD942F93E @default.
- Q37473017 P433 Q37473017-89E02283-171D-49C1-90C8-DCF0FE5583C3 @default.
- Q37473017 P478 Q37473017-235E2900-D407-4BD2-932C-7449F934F86C @default.
- Q37473017 P50 Q37473017-0C1696D5-4A9D-4DFA-A256-915D496FFD9E @default.
- Q37473017 P50 Q37473017-8A65C41A-51DB-461A-902B-D2F4370180EE @default.
- Q37473017 P50 Q37473017-ABDB94F7-FE1A-4125-AC99-25DF9B6F7504 @default.
- Q37473017 P577 Q37473017-2448E538-3AB8-4DB8-BF8C-EBD396125914 @default.
- Q37473017 P5875 Q37473017-8FBABA5D-2DD2-4035-981A-14689342F11C @default.
- Q37473017 P698 Q37473017-F5093358-4D6B-423F-80EE-345CD54CFE60 @default.
- Q37473017 P921 Q37473017-3160D3A6-8231-4C26-8BE6-A74C31F71735 @default.
- Q37473017 P921 Q37473017-5021CE95-EB5B-466F-BAFC-1A7524BDC168 @default.
- Q37473017 P921 Q37473017-F9BC090A-71C5-4A0A-AA3B-BF9B891E6125 @default.
- Q37473017 P932 Q37473017-C9E6527B-288D-4955-B476-4E428F50F98D @default.
- Q37473017 P356 CIT696 @default.
- Q37473017 P698 24145879 @default.
- Q37473017 P1433 Q5133764 @default.
- Q37473017 P1476 "Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years" @default.
- Q37473017 P2093 "Andrew Wiznia" @default.
- Q37473017 P2093 "Bobbie Graham" @default.
- Q37473017 P2093 "Brenda Homony" @default.
- Q37473017 P2093 "Carmelita Alvero" @default.
- Q37473017 P2093 "Carol Worrell" @default.
- Q37473017 P2093 "Edward P Acosta" @default.
- Q37473017 P2093 "Hedy Teppler" @default.
- Q37473017 P2093 "International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1066 Study Team" @default.
- Q37473017 P2093 "Larissa Wenning" @default.
- Q37473017 P2093 "Nan Zheng" @default.
- Q37473017 P2093 "Stephen A Spector" @default.
- Q37473017 P2093 "Terence Fenton" @default.
- Q37473017 P2093 "Xia Xu" @default.
- Q37473017 P2860 Q28288290 @default.
- Q37473017 P2860 Q37379360 @default.
- Q37473017 P2860 Q43189964 @default.
- Q37473017 P2860 Q43275867 @default.
- Q37473017 P2860 Q43282292 @default.
- Q37473017 P2860 Q43300648 @default.
- Q37473017 P2860 Q45363261 @default.
- Q37473017 P2860 Q46631439 @default.
- Q37473017 P2860 Q61314901 @default.
- Q37473017 P304 "413-422" @default.
- Q37473017 P31 Q13442814 @default.
- Q37473017 P356 "10.1093/CID/CIT696" @default.
- Q37473017 P407 Q1860 @default.
- Q37473017 P433 "3" @default.
- Q37473017 P478 "58" @default.
- Q37473017 P50 Q42538246 @default.
- Q37473017 P50 Q42538604 @default.